Lexicon Pharmaceuticals, Inc. - Common Stock (NQ:LXRX)

An analyst at a prominent research firm initiated coverage of the

Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today ↗

September 28, 2026

Performance

52-Week Range 44.4% below 52-week high

1.490

1.1052W Low 2.6852W High

1 Week 11.3% below 1-week high

1.511W Low 1.681W High

Lexicon Pharmaceuticals, Inc. - Common Stock (LXRX) traded between $1.10 and $2.68 over the past 52 weeks and last traded at $1.49, 44.4% below its 52-week high. Over the past week it ranged between $1.51 and $1.68.

Past 12 Months

-9.7%

-27.0%

-33.8%

-18.1%

+30.7%

+3.5%

1W -$0.16

1M -$0.55

3M -$0.76

6M -$0.33

YTD +$0.35

1Y +$0.05

LXRX was +3.5% over the past year, -18.1% over six months, +30.7% year to date, -9.7% in the last week.

12 Months vs Market

LXRX

+3.5%

DIA

+12.5%

SPY

+13.8%

QQQ

+15.2%

IWM

+12.0%

Over the past 12 months LXRX returned +3.5% versus DIA (Dow) +12.5%, SPY (S&P 500) +13.8%, QQQ (Nasdaq 100) +15.2% and IWM (Russell 2000) +12.0%.

Volume & Liquidity 0.47× 3-mo avg

Today 1,318,497 3-mo avg 2.8M

1.6M

2.8M

3.0M

YTD

2.9M

2.7M

LXRX most recently traded 1,318,497 shares against a 3-month average daily volume of 2.8M.

More News

Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data ↗

September 20, 2026

Via MarketBeat

Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences

September 01, 2026

Lexicon Pharmaceuticals (NASDAQ:LXRX) Scores Perfect 10 Technical Rating After 119% Rally ↗

Lexicon Pharmaceuticals (NASDAQ:LXRX) Falls as Q2 Revenue Misses Estimates ↗

August 06, 2026

Via Chartmill

July 08, 2026

Via Chartmill

Lexicon Pharmaceuticals (NASDAQ:LXRX) Q1 2026 Results Show Revenue Beat and Narrowed Loss ↗

May 07, 2026

Via Chartmill

Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure

August 31, 2026

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

August 24, 2026

Lexicon (LXRX) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Lexicon Pharmaceuticals Q2 Earnings Call Highlights ↗

August 06, 2026

Via MarketBeat

August 06, 2026

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

July 30, 2026

Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)

July 27, 2026

Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026? ↗

June 11, 2026

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

June 03, 2026

Lexicon (LXRX) Q1 2026 Earnings Transcript ↗

June 01, 2026

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

May 28, 2026

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

May 12, 2026

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

Lexicon Pharmaceuticals Q1 Earnings Call Highlights ↗

May 08, 2026

Via MarketBeat

May 07, 2026

Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

May 04, 2026

Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

April 30, 2026

Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting

April 17, 2026

Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo

March 24, 2026